What does the product information recommend about breastfeeding during treatment with Parsabiv (etelcalcetide hydrochloride)?

For Parsabiv (etelcalcetide hydrochloride), decide whether to discontinue breastfeeding or discontinue/abstain from therapy, weighing breastfeeding benefits for the child against therapy benefits for the woman, because presence in human milk is unknown, rat milk excretion occurs, and risk to breastfed newborns/infants cannot be excluded.